Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Our vision is to be a world-class commercial biotechnology company. We believe that we can achieve this with an approach of focused excellence in everything that we do-in working efficiently, in making data-driven decisions quickly, and in advancing promising compounds rapidly. Already, we have built one of the most impressive oncology development pipelines in the biotechnology and pharmaceutical industries.
More >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.72
Change (%) Stock is Up 0.02 (1.18%)
Volume2,125,940
Data as of 09/18/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
09/17/14Exelixis Announces Cobimetinib Phase 3 coBRIM Results to Be Presented at ESMO 2014 CongressPrinter Friendly Version
09/08/14Exelixis to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 9Printer Friendly Version
09/01/14Exelixis Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate CancerPrinter Friendly Version
07/31/14Exelixis Announces Second Quarter 2014 Financial ResultsPrinter Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation2013 Annual Report (pdf)
Download Documentation2012 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.